CROI 2022

CROI 2022
February 12-16, 2022
Virtual Conference

Conference on Retroviruses and Opportunistic Infections.

Explore more information for Gilead HIV / AIDS therapies
Results (14)

Evaluation of HIV-1 Recency Assays Among Prospectively Observed HIV-1 Seroconversions

Viral and Biomarker Outcomes of an Engineered bNAb in ART-Suppressed Participants

Remdesivir Treatment for COVID-19 in Hospitalized Children: CARAVAN Interim Results

Immunological and Glycomic Correlates of Time to HIV Rebound in Viremic Controllers

Immunogenicity and Prophylactic Efficacy of Arenavirus-Based SIV Vaccine in Macaques

Remdesivir in an Outpatient Setting Improves Biomarkers for Progression of COVID-19

Pharmacokinetics of Lenacapavir in Participants With Severe Renal Impairment

Safety of Remdesivir vs Placebo in Nonhospitalized Patients With COVID-19

Evaluation of Potential Drug-Drug Interactions Between Islatravir and Lenacapavir

B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults

Long Acting Lenacapavir Protects Against Intravenous Challenge with Simian-Tropic HIV

Long-Acting Lenacapavir in People With Multidrug-Resistant HIV-1: Week 52 Results

Absence of Cross-Resistance to Lenacapavir in HIV Entry Inhibitor-Resistant Isolates

Lenacapavir as part of a Combination Regimen in Treatment-Naïve People with HIV: Week 54 Results